Zentalis Prices 23M Share Offering at $3.50, a 6.6% Discount
ZNTL has more than doubled off its 52-week low of $1.212.
Summary
Zentalis priced its underwritten public offering of 23 million shares at $3.50 per share, a 6.6% discount to the last close of $3.748. The offering raises approximately $80.5 million before underwriting discounts and expenses. The company also plans to use net proceeds for precommercial activities, capital expenditure, working capital, and other general corporate purposes. The offering is expected to close on Aug. 17, and underwriters have a 30-day option to purchase up to an additional 3.45 million shares. The offering is dilutive to existing shareholders by roughly 32% based on the current share count. Zentalis had $174.6 million in cash as of Q2 2026 with runway into late 2027, so this raise extends the runway further.
At the time of this announcement, ZNTL was trading at $3.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $297.4M. The 52-week trading range was $1.21 to $6.95. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.